Charles Mantel is an accomplished inventor based in Indianapolis, IN (US). He has made significant contributions to the field of biomedical research, particularly in the area of myeloid cell suppression. With a total of 2 patents, Mantel's work has the potential to impact therapeutic strategies for various diseases.

Latest Patents

Mantel's latest patents include innovative methods for suppressing myeloid cells using chemokines. The first patent describes preferred processes and compositions for suppressing myeloid cells in mammals. These processes involve the use of chemokines in synergistic combinations or while they are substantially completely in monomeric form, meaning they are largely free from their polymerized or aggregated forms. The second patent focuses on compositions of myeloid-cell-suppressive chemokines. This patent outlines processes for suppressing the proliferation of or for myeloprotecting myeloid cells in mammals. The processes utilize chemokines such as Macrophage Inflammatory Protein-2.alpha. (MIP-2.alpha.), Platelet Factor 4 (PF4), Interleukin-8 (IL-8), and Macrophage Chemotactic and Activating Factor (MCAF). These chemokines can be used in synergistic combinations or while they are also substantially free from their polymerized or aggregated forms.

Career Highlights

Mantel is affiliated with Indiana University, where he conducts his research and development work. His contributions to the field have been recognized through his patents and ongoing research efforts.

Collaborations

Some of his notable coworkers include Hal E Broxmeyer and Scott Cooper, who have collaborated with Mantel on various research projects.

Conclusion

Charles Mantel's innovative work in the field of myeloid cell suppression showcases his dedication to advancing biomedical research. His patents reflect a commitment to developing effective therapeutic strategies that could benefit many.